Ultraviolet and laser therapy

  • Rahat S. Azfar
  • Abby S. Van Voorhees
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

Natural sunlight’s beneficial effect on psoriasis has been long known. This observation led over the past century to the utilization of artificial light sources for the treatment of psoriasis. For over seven decades, phototherapy using artificial ultraviolet light has been an established standard in the treatment of psoriasis. Advancements in our understanding of ultraviolet energy and photobiology have led to a number of available modalities in this field. After a brief historical introduction, we will discuss these techniques in detail, with emphasis on indications, efficacy, advantages and disadvantages and administration of each modality.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lebwohl M, Ting PT, Koo JY (2005) Psoriasis treatment: traditional therapy. Ann Rheum Dis 64S2: ii83–86Google Scholar
  2. 2.
    Ingram JT (1953) The approach to psoriasis. Br J Dermatol 2: 591–594Google Scholar
  3. 3.
    Stuttgen G (1997) History of treatments. Clin Dermatol 15: 693–703PubMedGoogle Scholar
  4. 4.
    Zanolli M (2004) Phototherapy arsenal in the treatment of psoriasis. Dermatol Clin 22: 397–406PubMedGoogle Scholar
  5. 5.
    Green C, Diffey BL, Hawk JL (1992) Ultraviolet radiation in the treatment of skin disease. Physics Med Biol 37(1): 1–20Google Scholar
  6. 6.
    Naldi L, Griffiths CEM (2005) Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. B J Dermatol 152(4): 597–615Google Scholar
  7. 7.
    Bonis B, Kemeny L, Dobozy A, Bor Z, Szabo G, Ignacz F (1997) 308 nm UVB excimer laser for psoriasis. Lancet 350(9090): 1522PubMedGoogle Scholar
  8. 8.
    Hacker SM, Rasmussen JE (1992) The effect of flash lamp-pulsed dye laser on psoriasis. Arch Dermatol 128: 853–855PubMedGoogle Scholar
  9. 9.
    Al-Ajmi HS (2006) A comparison of minimal erythema doses for narrowband versus broadband ultraviolet B irradiation in darkly pigmented healthy subjects and in psoriatic patients in Kuwait. Br J Dermatol 154: 774–807Google Scholar
  10. 10.
    Lebwohl M (2000) Advances in psoriasis therapy. Dermatol Clin 18(1): 13–9, viiPubMedGoogle Scholar
  11. 11.
    Coven TR, Burack LH, Gilleaudeau P, Keogh M, Ozawa M, Kreuger JG (1997) Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe-psoriasis in patients compared with broadband UV-B. Arch Dermatol 133(12): 1514–1522PubMedGoogle Scholar
  12. 12.
    Dawe RS (2003) A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis. Br J Dermatol 149: 669–672PubMedGoogle Scholar
  13. 13.
    Berneburg M, Rocken M, Benedix F (2005) Phototherapy with narrowband versus broadband UVB. Acta Derm Venereol 85(2): 98–108PubMedGoogle Scholar
  14. 14.
    Bandow GD, Koo JYM (2004) Narrow-band ultraviolet B radiation: a review of the current literature. Int J Dermatol 43: 555–561PubMedGoogle Scholar
  15. 15.
    Weishcer M, Blum A, Eberhard F, Rocken M, Berneburg M (2004) No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB photo therapy: a first retrospective study. Acta Derm Venereol 84: 370–374Google Scholar
  16. 16.
    Man I, Crombie IK, Dawe RS, Ibbotson SH, Ferguson J (2005) The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol 152: 755–757PubMedGoogle Scholar
  17. 17.
    Lee E, Koo J, Berger T (2005) UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 44(5): 355–360PubMedGoogle Scholar
  18. 18.
    Ibbotson SH, Bilsland D, Cox NH, Dawe RS, Diffey B, Edwards C, Farr PM, Ferguson J, Hart G, Hawk J (2004) An update and guidance on narrowband ultraviolet B photo therapy: a British Photodermatology Group Workshop Report. Br J Dermatol 151: 283–297PubMedGoogle Scholar
  19. 19.
    Green C, Ferguson J, Lakshmipathi T, Johnson BE (1988) 311 nm UVB phototherapy — an effective treatment for psoriasis. Br J Dermatol 119(6): 691–696PubMedGoogle Scholar
  20. 20.
    Kenicer KJA, Lakshmipathi T, Addo HA (1981) An assessment of the effect of photochemotherapy (PUVA) and UVB phototherapy in the treatment of psoriasis. Br J Dermatol 105: 629–639PubMedGoogle Scholar
  21. 21.
    Eells LD, Wolff JM, Garloff J, Eaglstein WH (1984) Comparison of suberythemogenic and maximally aggressive ultraviolet B therapy for psoriasis. J Am Acad Dermatol 11(1): 105–110PubMedGoogle Scholar
  22. 22.
    Cameron H, Dawe RS, Yule S, Murphy J, Ibbotson SH, Ferguson J (2002) A randomized, observer-blinded trial of twice versus three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 147(5): 973–978PubMedGoogle Scholar
  23. 23.
    Dawe RS, Wainwright NJ, Cameron H, Ferguson J (1998) Narrowband (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 138: 833–839PubMedGoogle Scholar
  24. 24.
    Leenutaphong V, Nimkulrat P, Sudtim S (2000) Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed 16: 202–206PubMedGoogle Scholar
  25. 25.
    Otman SG, Edwards C, Pearse AD, Gambles BJ, Anstey AV (2006) Modulation of ultraviolet (UV) transmission by emollients: relevance to narrowband UVB phototherapy and psoralen plus UVA photochemotherapy. Br J Dermatol 154(5): 963–968PubMedGoogle Scholar
  26. 26.
    Berne B, Blom I, Spangberg S (1990) Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base. A single-blind controlled study. Acta Dermato-Venereologica 70(6): 474–477PubMedGoogle Scholar
  27. 27.
    Penven K, Leroy D, Verneuil L, Faguer K, Dompmartin A (2005) Evaluation of vaseline oil applied prior to UVB TL01 phototherapy in the treatment of psoriasis. Photodermatol Photoimmunol Photomed 21(3): 138–141PubMedGoogle Scholar
  28. 28.
    Fetil E, Ozka S, Soyal MC, Ilknur T, Erdem Y, Gunes AT (2002) Effects of topical petrolatum and salicylic acid on the erythemogenicity of UVB. Eur J Dermatol 12: 154–156PubMedGoogle Scholar
  29. 29.
    Lebwohl M, Martinez J, Weber P, DeLuca R (1995) Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol 32(3): 469–471PubMedGoogle Scholar
  30. 30.
    Kristensen B, Kristensen O (1991) Topical salicylic acid interferes with UVB therapy for psoriasis. Acta Derm Venereol 71(1): 37–40PubMedGoogle Scholar
  31. 31.
    Harber LC, Armstrong RB, Leach EE (1981) Preliminary report: Modified Goeckerman therapy for hospitalized patients: Ambulatory day care center and improved quantitative dosimetry. J Invest Dermatol 77: 162–166PubMedGoogle Scholar
  32. 32.
    Armstrong RB, Leach EE, Fleiss JL, Harber LC (1984) Modified Goeckerman therapy for psoriasis. A two-year follow-up of a combined hospital-ambulatory care program. Arch Dermatol 120: 313–318PubMedGoogle Scholar
  33. 33.
    Lee E, Koo J (2005) Modern modified ‘ultra’ Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. J Dermatol Treat 16: 102–107Google Scholar
  34. 34.
    Marsico AR, Eaglstein WH, Weinstein GD (1976) Ultraviolet light and tar in the Goeckerman treatment of psoriasis. Arch Dermatol 112: 1249–1250PubMedGoogle Scholar
  35. 35.
    Petrozzi JW, Barton JO, Kaidbey KK, Kligman AM (1978) Updating the Goeckerman regimen for psoriasis. Br J Dermatol 98: 437–444PubMedGoogle Scholar
  36. 36.
    Lowe NJ, Wortzman MS, Breeding J, Koudsi H, Taylor L (1983) Coal tar phototherapy for psoriasis reevaluated: erythemogenic versus suberythemogenic ultraviolet with a tar extract in oil and crude coal tar. J Am Acad Dermatol 8: 781–789PubMedGoogle Scholar
  37. 37.
    Dodd WA (1993) Tars. Their role in the treatment of psoriasis. Dermatol Clin 11(1): 131–135PubMedGoogle Scholar
  38. 38.
    Menter A, Cram DL (1983) The Goeckerman regimen in two psoriasis day care centers. J Am Acad Dermatol 9: 59–65PubMedGoogle Scholar
  39. 39.
    Koo J, Lebwohl M (1999) Duration of remission of psoriasis therapies. J Am Acad Dermatol 41: 51–59PubMedGoogle Scholar
  40. 40.
    Borska L, Fiala Z, Smejkalova J, Hamakova K, Kremlacek J (2004) Possible genotoxic risk of combined exposure to pharmaceutical coal tar and UV-B radiation. Central Eur J Public Health 12: S14–15Google Scholar
  41. 41.
    Pion IA, Koenig KL, Lim HW (1995) Is dermatologic usage of coal tar carcinogenic? A review of the literature. Dermatol Surg 21: 227–231PubMedGoogle Scholar
  42. 42.
    Pittelkow MR, Perry HO, Muller SA, Maughan WZ, O’Brien PC (1981) Skin cancer in patients with psoriasis treated with coal tar: a 25 year follow-up study. Arch Dermatol 117: 465–468PubMedGoogle Scholar
  43. 43.
    Ryatt KS, Statham BN, Rowell NR (1984) Short-contact modification of the Ingram regime. Br J Dermatol 111(4): 455–459PubMedGoogle Scholar
  44. 44.
    McBride SR, Walker P, Reynolds NJ (2003) Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol 149: 1259–1265PubMedGoogle Scholar
  45. 45.
    Karvonen J, Kokkonen EL, Ruotsalainen E (1989) 311 nm UVB lamps in the treatment of psoriasis with the Ingram regimen. Acta Derm Venereol 69(1): 82–85PubMedGoogle Scholar
  46. 46.
    Seville RH (1975) Simplified dithranol treatment for psoriasis. Br J Dermatol 93: 205–208PubMedGoogle Scholar
  47. 47.
    Statham BN, Ryatt KS, Rowell NR (1984) Short-contact dithranol therapy — a comparison with the Ingram regime. Br J Dermatol 110: 703–708PubMedGoogle Scholar
  48. 48.
    Paramsothy Y, Collins M, Lawrence CM (1988) Effect of UVB therapy and a coal tar bath on short contact dithranol treatment for psoriasis. Br J Dermatol 118: 783–789PubMedGoogle Scholar
  49. 49.
    Behrens S, Grundmann-Kollman M, Schiener R, Peter RU, Kerscher M (2000) Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 42: 493–495PubMedGoogle Scholar
  50. 50.
    van de Kerkhof PCM (2006) Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 19(5): 252–263PubMedGoogle Scholar
  51. 51.
    Takahashi H, Ibe M, Kinouchi M, Ishida-Yamamoto A, Hashimoto Y, Iizuka H (2003) Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 31(1): 21–28PubMedGoogle Scholar
  52. 52.
    Berneburg M, Röcken M, Benedix F (2005) Phototherapy with Narrowband versus Broadband UVB. Phototherapy with Narrowband versus Broadband UVB. Acta Derm Venereol 85: 98–108PubMedGoogle Scholar
  53. 53.
    Roussaki-Schulze AV, Kouskoukis C, Klimi E, Zafiriou E, Galanos A, Rallis E (2005) Calcipotriol monotherapy versus calcipotriol plus UVA1 versus calcipotriol plus narrow-band UVB in the treatment of psoriasis. Drugs Exper Clin Res 31(5–6): 169–174Google Scholar
  54. 54.
    Brazzelli V, Barbagallo T, Prestinari F, Rona C, De Silvestri A, Trevisan V, Borroni G (2005) Noninvasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: “right-left intra-individual pre/post comparison design”. Int J Immunopath Pharm 18(4): 755–760Google Scholar
  55. 55.
    Molin L (1999) Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology 198(4): 375–381PubMedGoogle Scholar
  56. 56.
    Messer G, Degitz K, Plewig G, Rocken M (2001) Pretreatment of psoriasis with the vitamin D3 derivative tacalcitol increases the responsiveness to 311-nm ultraviolet B: results of a controlled, right/left study. Pretreatment of psoriasis with the vitamin D3 derivative tacalcitol increases the responsiveness to 311-nm ultraviolet B: results of a controlled, right/left study. Br J Dermatol 144(3): 628–629PubMedGoogle Scholar
  57. 57.
    Rim JH, Choe YB, Youn JI (2002) Positive effect of using calcipotriol ointment with narrow-band ultraviolet B phototherapy in psoriatic patients. Photodermatol Photoimmunol Photomed 18: 131–134PubMedGoogle Scholar
  58. 58.
    Ring J, Kowalzick L, Christophers E, Schill WB, Schopf E, Stander M, Wolff HH, Altmeyer P (2001) Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol 144: 495–499PubMedGoogle Scholar
  59. 59.
    Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE (2000) Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol 136(12): 1536–1543PubMedGoogle Scholar
  60. 60.
    Woo WK, McKenna KE (2003) Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol 149(1): 146–150PubMedGoogle Scholar
  61. 61.
    de Rie MA, de Hoop D, Jonsson L, Bakkers EJ, Sorensen M (2001) Pharmacoeconomic evaluation of calcipotriol (Daivonex/Dovonex) and UVB phototherapy in the treatment of psoriasis: a Markov model for The Netherlands. Dermatol 202(1): 38–43Google Scholar
  62. 62.
    Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M (2000) Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatol 200(1): 17–24Google Scholar
  63. 63.
    Molin L (1999) Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatol 198(4): 375–381Google Scholar
  64. 64.
    Lebwohl M, Quijije J, Gilliard J, Rollin T, Watts O (2003) Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol 121(3): 594–595PubMedGoogle Scholar
  65. 65.
    Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B (1997) Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol 37(1): 93–95PubMedGoogle Scholar
  66. 66.
    McKenna KE, Stern RS (1995) Photosensitivity associated with combined UV-B and calcipotriene therapy. Arch Dermatol 131(11): 1305–1307PubMedGoogle Scholar
  67. 67.
    Meola T, Soter NA, Lim HW (1991) Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? A review of the literature. Arch Dermatol 127(11): 1708–1713PubMedGoogle Scholar
  68. 68.
    Lebwohl M, Menter A, Koo J, Feldman SR (2004) Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 50(3): 416–430PubMedGoogle Scholar
  69. 69.
    Matz H, Orion E, Wolf R (2003) Balneotherapy in dermatology. Dermatol Ther 16(2): 132–140PubMedGoogle Scholar
  70. 70.
    Hodak E, Gottlieb AB, Segal T, Politi Y, Maron L, Sulkes J, David M (2003) Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation. J Am Acad Dermatol 49(3): 451–457PubMedGoogle Scholar
  71. 71.
    Tsoureli-Nikita E, Menchini G, Ghersetich I, Hercogova J (2002) Alternative treatment of psoriasis with balneotherapy using Leopoldine spa water. J Eur Acad Dermatol Venereol 16(3): 260–262PubMedGoogle Scholar
  72. 72.
    Holló P, Gonzalez R, Kása M, Horváth A (2005) Synchronous balneophototherapy is effective for the different clinical types of psoriasis. J Eur Acad Dermatol Venereol 19(5): 578–581PubMedGoogle Scholar
  73. 73.
    Léauté-Labrèze C, Saillour F, Chene G, Cazenave C, Luxey-Bellocq ML, Sanciaume C, Toussaint JF, Taieb A (2001) Saline spa water or combined water and UV-B for psoriasis versus conventional UV-B: lessons from the Salies de Béarn randomized study. Arch Dermatol 137: 1035–1039PubMedGoogle Scholar
  74. 74.
    Harari M, Shani J (1997) Demographic evaluation of successful antipsoriatic climatotherapy at the Dead Sea (Israel) DMZ clinic. Int J Dermatol 36: 304–308PubMedGoogle Scholar
  75. 75.
    David M, Efron D, Hodak E, Even-Paz Z (2000) Treatment of psoriasis at the Dead Sea: Why, how and when? IMAJ 2: 232–234PubMedGoogle Scholar
  76. 76.
    Dawe RS, Yule S, Cameron H, Moseley H, Ibbotson SH, Ferguson J (2005) A randomized controlled comparison of the efficacy of Dead Sea salt balneophototherapy versus narrowband ultraviolet B monotherapy for chronic plaque psoriasis. Br J Dermatol 153(3): 613–619PubMedGoogle Scholar
  77. 77.
    Larko O, Swanbeck G (1979) Home solarium treatment of psoriasis. B J Dermatol 101: 13–16Google Scholar
  78. 78.
    Cameron H, Yule S, Moseley H, Dawe RS, Ferguson J (2002) Taking treatment to the patient: development of a home TL-01 ultraviolet B phototherapy service. Br J Dermatol 147: 957–965PubMedGoogle Scholar
  79. 79.
    Yelverton CB, Kulkarni AS, Balkrishnan R, Feldman SR (2006) Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis. Managed Care Interface 19(1): 33–36, 39PubMedGoogle Scholar
  80. 80.
    Koek MBG, Buskens E, Bruijnzeel-Koomen CAFM, Sigurdsson V (2006) Home ultraviolet B phototherapy for psoriasis: discrepancy between literature, guidelines, general opinions and actual use. Results of a literature review, a web search, and a questionnaire among dermatologists. B J Dermatol 154: 701–711Google Scholar
  81. 81.
    Sarkany RPE, Anstey A, Diffey BL, Jobling R, Langmack K, McGregor JM, Moseley H, Murphy GM, Rhodes LE, Norris PG; British Photodermatology Group (1999) Home phototherapy: report on a workshop of the British Photodermatology Group, December 1996. Br J Dermatol 140: 195–199PubMedGoogle Scholar
  82. 82.
    Ruzicka T, Sommerburg C, Braun-Falco O, Koster W, Lengen W, Lensing W, Letzel H, Meigel WN, Paul E, Przybilla B et al. (1990) Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 126: 482–486PubMedGoogle Scholar
  83. 83.
    Iest J, Boer J (1989) Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 120: 665–670PubMedGoogle Scholar
  84. 84.
    Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R (1991) Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 24(4): 591–594PubMedGoogle Scholar
  85. 85.
    Spuls PI, Rozenblit M, Lebwohl M (2003) Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatol Treat 14(S2): 17–20Google Scholar
  86. 86.
    Green C, Lakshmipathi T, Johnson BE, Ferguson JA (1992) Comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy versus etretinate (re-TL-01) versus etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br J Dermatol 127: 5–9PubMedGoogle Scholar
  87. 87.
    Kopp T, Karlhofer F, Szepfalusi Z, Schneeberger A, Stingl G, Tanew A (2004) Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol 151: 912–916PubMedGoogle Scholar
  88. 88.
    Asawanonda P, Nateetongrungsak Y (2006) Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 54(6): 1013–1018PubMedGoogle Scholar
  89. 89.
    Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA (1982) Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 7(6): 758–762PubMedGoogle Scholar
  90. 90.
    de Berker DA, Sakuntabhai A, Diffey BL, Matthews JN, Farr PM (1997) Comparison of psoralen-UVB and psoralen-UVA photochemotherapy in the treatment of psoriasis. J Am Acad Dermatol 36: 5775–5781Google Scholar
  91. 91.
    Shamsuddin S, Haroon TS (2003) Comparative study of psoralen-UVB versus UVB-alone therapy in the treatment of psoriasis. J Pak Assoc Dermatol 13: 55–61Google Scholar
  92. 92.
    Ortel B, Perl S, Kinaciyan T, Calzavara-Pinton PG, Hönigsmann H (1993) Comparison of narrow-band (311 nm) UVB and broad-band UVA after oral or bath-water 8-methoxypsoralen in the treatment of psoriasis, J Am Acad Dermatol 29: 736–740PubMedGoogle Scholar
  93. 93.
    Amornpinyokeit N, Asawanonda P (2006) 8-methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis. Photodermatol Photoimmunol Photomed 22: 285–289PubMedGoogle Scholar
  94. 94.
    Bianchi B, Campolmi P, Mavilia L, Danesi A, Rossi R, Cappugi P (2003) Monochromatic excimer light (308 nm): an immunohistochemical study of cutaneous T cells and apoptosis-related molecules in psoriasis. J Eur Acad Dermatol Venerol 17: 408–413Google Scholar
  95. 95.
    Novák Z, Bónis B, Baltás E, Ocsovszki I, Ignácz F, Dobozy A, Kemény L (2002) Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol 67: 32–38Google Scholar
  96. 96.
    Taibjee SM, Cheung ST, Laube S, Lanigan SW (2005) Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis. Br J Dermatol 153(5): 960–966PubMedGoogle Scholar
  97. 97.
    Bonis B, Kemeny L, Dobozy A, Bor Z, Szabo G, Ignacz F (1997) 308 nm UVB excimer laser for psoriasis. Lancet 350: 1522PubMedGoogle Scholar
  98. 98.
    Gerber W, Arheilger B, Ha TA, Hermann J, Ockenfels HM (2003) Ultraviolet B 308-nm excimer laser treatment of psoriasis: a new phototherapeutic approach. Br J Dermatol 149: 1250–1258PubMedGoogle Scholar
  99. 99.
    Mafong EA, Friedman PM, Kauvar AN, Bernstein LJ, Alexiades-Armenakas M, Geronemus RG (2002) Treatment of inverse psoriasis with the 308 nm excimer laser. Dermatol Surg 28(6): 530–532PubMedGoogle Scholar
  100. 100.
    Taylor CR, Racette AL (2004) A 308-nm excimer laser for the treatment of scalp psoriasis. Laser Surg Med 34(2): 136–140Google Scholar
  101. 101.
    Neumann NJ, Mahnke N, Korpusik D, Stege H, Ruzicka T (2006) Treatment of palmoplantar psoriasis with monochromatic excimer light (308-nm) versus cream PUVA. Acta Derm Venereol 86: 22–24PubMedGoogle Scholar
  102. 102.
    Acland KM, Barlow BJ (2000) Lasers for the dermatologist. B J Dermatol 143: 244–255Google Scholar
  103. 103.
    Zelickson BD, Mehregan DA, Wendelschfer-Crabb G, Ruppman D, Cook A, O’Connell P, Kennedy WR (1996) Clinical and histologic evaluation of psoriatic plaques treated with a flashlamp pulsed dye laser. J Am Acad Dermatol 35: 64–68PubMedGoogle Scholar
  104. 104.
    Hern S, Allen MH, Sousa AR, Harland CC, Barker JNWN, Levick JR, Mortimer PS (2001) Immunohistochemical evaluation of psoriatic plaques following selective photothermolysis of the superficial capillaries. Br J Dermatol 145: 45–53PubMedGoogle Scholar
  105. 105.
    de Leeuw J, Tank B, Bjerring PJ, Koetsveld S, Neumann M (2006) Concomitant treatment of psoriasis of the hands and feet with pulsed dye laser and topical calcipotriol, salicylic acid, or both: a prospective open study in 41 patients. J Am Acad Dermatol 54(2): 266–271PubMedGoogle Scholar
  106. 106.
    Erceg A, Bovenschen HJ, van de Kerkhof PCM, Seyger MMB (2006) Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. B J Dermatol 155: 110–114Google Scholar
  107. 107.
    Su J, Pearce DJ, Feldman SR (2005) The role of commercial tanning beds and ultraviolet A light in the treatment of psoriasis. J Dermatol Treatment 16(5/6): 324–326Google Scholar
  108. 108.
    Turner RJ, Walshaw D, Diffey BL, Farr PM (2000) A controlled study of ultraviolet A sunbed treatment of psoriasis. Br J Dermatol 143: 957–963PubMedGoogle Scholar
  109. 109.
    Coven TR, Walters IB, Cardinale I, Krueger JG (1999) PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis. Photodermatol Photoimmunol Photomed 15: 22–27PubMedGoogle Scholar
  110. 110.
    Tanew A, Ortel B, Honigsmann H (1999) Half-side comparison of erythemogenic versus suberythemogenic UVA doses in oral photochemotherapy of psoriasis. J Am Acad Dermatol 41(3 Pt 1): 408–413PubMedGoogle Scholar
  111. 111.
    Methoxsalen: drug information. 1978–2006 Lexi-Comp, IncGoogle Scholar
  112. 112.
    Stern RS, Lunder EJ (1998) Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 134: 1582–1585PubMedGoogle Scholar
  113. 113.
    Stern RS, Bagheri S, Nichols K (2002) The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 47: 33PubMedGoogle Scholar
  114. 114.
    Stern RS (1999) Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. N Eng J Med 322(16): 1093–1097Google Scholar
  115. 115.
    Stern RS and PUVA followup study (2001) The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 44: 755–761PubMedGoogle Scholar
  116. 116.
    Morison WL, Baughman RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, Lebwohl M, Lew R, Naldi L, Parrish JA et al. (1998) Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 134(5): 595–598PubMedGoogle Scholar
  117. 117.
    Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, Lindelof B, Berne B, Hannuksela M, Poikolainen K, Karvonen J (1999) Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 141(3): 497–501PubMedGoogle Scholar
  118. 118.
    Hannuksela-Svahn A, Pukkala E, Koulu L, Jansen CT, Karvonen J (1999) Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. J Am Acad Dermatol 40(5 Pt 1): 694–696PubMedGoogle Scholar
  119. 119.
    Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Johannesson A, Berne B, Ljunggren B, Andersson T, Molin L, Nylander-Lundqvist E et al. (1999) PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 141(1): 108–112PubMedGoogle Scholar
  120. 120.
    Vallat VP, Gilleaudeau P, Battat L, Wolfe J, Nabeya R, Heftler N, Hodak E, Gottlieb AB, Krueger JG (1994) PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 180: 283–296PubMedGoogle Scholar
  121. 121.
    Fairhurst DA, Ashcroft DM, Griffiths CE (2005) Optimal management of severe plaque form of psoriasis. Am J Clin Dermatol 6: 283–294PubMedGoogle Scholar
  122. 122.
    Halpern SM, Anstey AV, Dawe RS, Diffey BL, Farr PM, Ferguson J, Hawk JL, Ibbotson S, McGregor JM, Murphy GM et al. (2000) Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. Br J Dermatol 142: 22–31PubMedGoogle Scholar
  123. 123.
    Oxsoralen-ultra capsules package insertGoogle Scholar
  124. 124.
    Grundmann-Kollmann M, Behrens S, Peter RU, Kerscher M (1999) Treatment of severe recalcitrant dermatoses of the palms and soles with PUVA-bath versus PUVA-cream therapy. Photodermatol Photoimmunol Photomed 15: 87–89PubMedGoogle Scholar
  125. 125.
    Schiener R, Gottlober P, Muller B, Williams S, Pillekamp H, Peter RU, Kerscher M (2005) PUVA-gel versus PUVA-bath therapy for severe recalcitrant palmoplantar dermatoses. A randomized, single-blinded prospective study. Photodermatol Photoimmunol Photomed 21: 62–67PubMedGoogle Scholar
  126. 126.
    Boyvat A, Erdi H, Birol A, Gurgey E (2000) Interaction of commonly used emollients with photochemotherapy. Photodermatol Photoimmunol Photomed 16(4): 156–160PubMedGoogle Scholar
  127. 127.
    Birgin B, Fetil E, Ilknur T, Tahsin Gunes A, Ozkan S (2005) Effects of topical petrolatum and salicylic acid upon skin photoreaction to UVA. Eur J Dermatol 15: 156–158PubMedGoogle Scholar
  128. 128.
    Hindson C, Diffey B, Lawlor F, Downey A (1983) Dithranol-UV-A phototherapy (DUVA) for psoriasis: a treatment without dressings. Br J Dermatol 108(4): 457–460PubMedGoogle Scholar
  129. 129.
    van de Kerkhof PCM (2001) Therapeutic strategies: rotational therapy and combinations. Clin Dermatol 26: 356–361Google Scholar
  130. 130.
    Speight EL, Farr PM (1994) Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 130(1): 79–82PubMedGoogle Scholar
  131. 131.
    Torras H, Aliaga A, Lopez-Estebaranz JL, Hernandez I, Gardeazabal J, Quintanilla E, Mascaro JM (2004) A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatol Treat 15: 98–103Google Scholar
  132. 132.
    Frappaz A, Thivolet J (1993) Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 3: 351–354Google Scholar
  133. 133.
    Kokelj F, Plozzer C, Torsello P (1997) Reduction of UV-A radiation induced by calcipotriol in the treatment of vulgar psoriasis with oral psoralen plus UV-A. Arch Dermatol 133: 668–669PubMedGoogle Scholar
  134. 134.
    Grundmann-Kollmann M, Behrens S, Krahn G, Leiter U, Ochsendorf F, Kaufmann R, Peter RU, Kerscher M (1999) Treatment of psoriasis with calcipotriene plus psoralen-UV-A-bath therapy. Arch Dermatol 135(7): 861–862PubMedGoogle Scholar
  135. 135.
    Tzaneva S, Honigsmann H, Tanew A, Seeber A (2002) A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 147(4): 748–753PubMedGoogle Scholar
  136. 136.
    Glaser R, Rowert J, Mrowietz U (1998) Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriatic patients. Br J Dermatol 139: 148–151PubMedGoogle Scholar
  137. 137.
    Scott LJ, Dunn CJ, Goa KL (2001) Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol 2: 95–120PubMedGoogle Scholar
  138. 138.
    Youn JI, Park BS, Chung JH, Lee JH (1997) Photoprotective effect of calcipotriol upon skin photoreaction to UVA and UVB. Photodermatol Photoimmunol Photomed 13(3): 109–114PubMedGoogle Scholar
  139. 139.
    Lebwohl M, Quijije J, Gilliard J, Rollin T, Watts O (2003) Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol 121(3): 594–595PubMedGoogle Scholar
  140. 140.
    Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B (1997) Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol 37(1): 93–95PubMedGoogle Scholar
  141. 141.
    Behrens S, Grundmann-Kollmann M, Peter RU, Kerscher M (1999) Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid. Br J Dermatol 141: 177PubMedGoogle Scholar
  142. 142.
    Schmoll M, Henseler T, Christophers E (1978) Evaluation of PUVA, topical corticosteroids and the combination of both in the treatment of psoriasis. Br J Dermatol 99: 693–702PubMedGoogle Scholar
  143. 143.
    Del Rosso J, Friedlander SF (2005) Corticosteroids: Options in the era of steroid-sparing therapy. J Am Acad Dermatol 53: S50–S58PubMedGoogle Scholar
  144. 144.
    Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P (1991) Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 25(4): 682–684PubMedGoogle Scholar
  145. 145.
    Saurat JH, Geiger JM, Amblard P, Beani JC, Boulanger A, Claudy A, Frenk E, Guilhou JJ, Grosshans E, Merot Y et al. (1988) Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 177(4): 218–224PubMedGoogle Scholar
  146. 146.
    Lauharanta J, Juvakoski T, Lassus A (1981) A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis. Br J Dermatol 104(3): 325–332PubMedGoogle Scholar
  147. 147.
    Vaatainen N, Hollmen A, Fraki JE (1985) Trimethylpsoralen bath plus ultraviolet A combined with oral retinoid (etretinate) in the treatment of severe psoriasis. J Am Acad Dermatol 12: 52–55PubMedGoogle Scholar
  148. 148.
    Muchenberger S, Schof E, Simon JC (1997) The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br J Dermatol 137: 587–589PubMedGoogle Scholar
  149. 149.
    Lebwohl M (2000) Advances in psoriasis therapy. Dermatol Clin 18: 13–19PubMedGoogle Scholar
  150. 150.
    Lebwohl M, Tannis C, Carrasco D (2003) Acitretin suppression of squamous cell carcinoma. J Dermatol Treat 14(s2): 3–6Google Scholar
  151. 151.
    Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB (1982) Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 6: 46–51PubMedGoogle Scholar
  152. 152.
    Shehzad T, Dar NR, Zakria M (2004) Efficacy of concomitant use of PUVA and methotrexate in disease clearance time in plaque type psoriasis. J Pakistan Med Assoc 54(9): 453–455Google Scholar
  153. 153.
    Stern RS, Laird N (1994) The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 73(11): 2759–2764PubMedGoogle Scholar
  154. 154.
    LeVine MJ (1981) Erythema resulting from suberythemogenic doses of ultraviolet radiation and methotrexate. Arch Dermatol 117(10): 656–658PubMedGoogle Scholar
  155. 155.
    Hunt MJ, Lee SH, Salisbury EL, Wills EJ, Armati R (1997) Generalized pustular psoriasis responsive to PUVA and oral cyclosporin therapy. Australas J Dermatol 38(4): 199–201PubMedGoogle Scholar
  156. 156.
    Petzelbauer P, Honigsmann H, Langer K, Anegg B, Strohal R, Tanew A, Wolff K (1990) Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 123(5): 641–647PubMedGoogle Scholar
  157. 157.
    Marcil I, Stern RS (2001) Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358: 1042–1045PubMedGoogle Scholar
  158. 158.
    Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L (2003) Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120(2): 211–216PubMedGoogle Scholar
  159. 159.
    Dawe RS (2003) Ultraviolet A phototherapy. Br J Dermatol 148: 626–637PubMedGoogle Scholar
  160. 160.
    Godar DE (1999) UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol 112: 3–12PubMedGoogle Scholar
  161. 161.
    Kowalzick L, Suckow M, Waldmann T, Ponnighaus J-M (1999) Mediumdose UV-A1 versus broad-band UV-B in psoriasis. Z Dermatol 185: 92–94Google Scholar
  162. 162.
    Tuchinda C, Kerr HA, Taylor CR, Jacobe H, Bergamo BM, Elmets C, Rivard J, Lim HW (2006) UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed 22: 247–253PubMedGoogle Scholar
  163. 163.
    Rivard J, Janiga J, Lim HW (2006) Tacrolimus ointment 0.1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis. J Drug Dermatol 5(6): 505–510Google Scholar
  164. 164.
    Roussaki-Schulze AV, Kouskoukis C, Klimi E, Zafiriou E, Galanos A, Rallis E (2005) Calcipotriol monotherapy versus calcipotriol plus UVA1 versus calcipotriol plus narrow-band UVB in the treatment of psoriasis. Drugs Exp Clin Res 31: 169–174PubMedGoogle Scholar
  165. 165.
    Boer J, Schothorst AA, Suurmond D (1981) Influence of UVA on the erythematogenic and therapeutic effects of UVB irradiation in psoriasis; photoaugmentation effects. J Invest Dermatol 76(1): 56–58PubMedGoogle Scholar
  166. 166.
    Momtaz-T K, Parrish JA (1984) Combination of psoralens and ultraviolet A and ultraviolet B in the treatment of psoriasis vulgaris: a bilateral comparison study. J Am Acad Dermatol 10(3): 481–486PubMedGoogle Scholar
  167. 167.
    Calzavara-Pinton P (1998) Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination. J Am Acad Dermatol 38(5 Pt 1): 687–690PubMedGoogle Scholar
  168. 168.
    Grundmann-Kollmann M, Ludwig R, Zollner TM, Ochsendorf F, Thaci D, Boehncke WH, Krutmann J, Kaufmann R, Podda M (2004) Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol 50(5): 734–739PubMedGoogle Scholar
  169. 169.
    Su J, Pearce DJ, Feldman SR (2005) The role of commercial tanning beds and ultraviolet A light in the treatment of psoriasis. J Dermatol Treatment 16(5/6): 324–326Google Scholar
  170. 170.
    Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC (2000) A systematic review of treatments for severe psoriasis. Health Technology Assessment (Winchester, England) 4(40): 1–125Google Scholar
  171. 171.
    Koo J, Bandow G, Feldman SR (2003) The art and practice of UVB phototherapy for the treatment of psoriasis. In: GD Weinstein, AB Gottleib (eds): Therapy of moderate-to-severe psoriasis. Marcel Dekker Inc, New York, 68–69Google Scholar
  172. 172.
    Ortonne JP, Khemis A, Koo JYM, Choi J (2005) An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 19: 556–563PubMedGoogle Scholar
  173. 173.
    Scheinfeld N (2005) Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B photo therapy with total clearing of psoriasis. Dermatol Online J 11(2): 7PubMedGoogle Scholar
  174. 174.
    Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL, Efalizumab Study Group (2006) Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 54(4 Suppl 1): S154–163PubMedGoogle Scholar
  175. 175.
    Moore A, Wright E, Ostrowski L, Moore T (2006) Etanercept and narrowband UVB combination therapy for plaque-type psoriasis shortens onset of action in both adults and children. J Am Acad Dermatol 54(3 Suppl 1): AB217Google Scholar
  176. 176.
    Yosipovitch G, Tang MBY (2002) Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. Drugs Aging 19(11): 847–863PubMedGoogle Scholar
  177. 177.
    Jury CS, McHenry P, Burden AD, Lever R, Bilsland D (2006) Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol 31(2): 196–199PubMedGoogle Scholar
  178. 178.
    Pasic A, Ceovic R, Lipozencic J, Husar K, Susic SM, Skerlev M, Hrsan D (2003) Phototherapy in pediatric patients. Pediatric Dermatol 20(1): 71–77Google Scholar
  179. 179.
    Stern RS, Nichols KT (1996) Therapy with orally administered methoxsalen and ultraviolet A radiation during childhood increases the risk of basal cell carcinoma. The PUVA Follow-up Study. J Pediatrics 129(6): 915–917Google Scholar
  180. 180.
    Holme SA, Anstey AV (2004) Phototherapy and PUVA photochemotherapy in children. Photodermatol Photoimmunol Photomed 20(2): 69–75PubMedGoogle Scholar
  181. 181.
    Pasic A, Ceovic R, Lipozencic J, Husar K, Susic SM, Skerlev M, Hrsan D (2003) Phototherapy in pediatric patients. Pediatric Dermatol 20(1): 71–77Google Scholar
  182. 182.
    Tauscher AE, Fleischer AB, Phelps KC, Feldman SR (2002) Psoriasis and pregnancy. J Cutan Med Surg 6(6): 561–570PubMedGoogle Scholar
  183. 183.
    Stern RS, Lange R (1991) Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol 127(3): 347–350PubMedGoogle Scholar
  184. 184.
    Lebwohl M (2005) A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol 53(1): S59–S69PubMedGoogle Scholar
  185. 185.
    Smit JV, de Jong EM, van Hooijdonk CA, Otero ME, Boezeman JB, van de Kerkhof PC (2004) Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol 51(2): 257–264PubMedGoogle Scholar
  186. 186.
    Smit JV, Franssen ME, de Jong EM, Lambert J, Roseeuw DI, De Weert J, Yocum RC, Stevens VJ, van De Kerkhof PC (2004) A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol 51(2): 249–256PubMedGoogle Scholar
  187. 187.
    Smit JV, De Jong EM, Van De Kerkhof PC (2003) Effects of oral bexarotene (targretin) on the minimal erythema dose for broadspectrum UVB light. Skin Pharmacol Appl Skin Physiol 16(4): 237–241PubMedGoogle Scholar
  188. 188.
    Magliocco MA, Pandya K, Dombrovskiy V, Christiansen L, Wong Y, Gottlieb AB (2006) A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. J Am Acad Dermatol 54(1): 115–118PubMedGoogle Scholar
  189. 189.
    Smits T, Kleinpenning MM, van Erp PEJ, van de Kerkhof PCM, Gerritsen MJP (2006) A placebo controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy patients with psoriasis. Br J Dermatol 155: 429–436PubMedGoogle Scholar
  190. 190.
    Beattie PE, Dawe RS, Ferguson J, Ibboston SH (2004) Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy. Clinical Exper Dermatol 29: 545–562Google Scholar
  191. 191.
    Morton CA, Brown SB, Collins S, Ibbotson S, Jenkinson H, Kurwa H, Langmack K, McKenna K, Moseley H, Pearse AD et al. (2002) Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 146: 552–567PubMedGoogle Scholar
  192. 192.
    Ibbotson SH (2002) Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 146: 178–188PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • Rahat S. Azfar
    • 1
  • Abby S. Van Voorhees
    • 1
  1. 1.Department of DermatologyUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations